Literature DB >> 23095909

History of primary immunodeficiency diseases.

Hans D Ochs1, Walter H Hitzig.   

Abstract

PURPOSE OF REVIEW: This issue of Current Opinion in Allergy and Clinical Immunology is focused on primary immunodeficiency diseases (PIDs). Like every disorder, PID has its own specific history, starting with the discovery of agammaglobulinemia in 1952 and still expanding at a rapid pace, covering, at the time of this publication, more than 180 genetically determined disorders. However, as this report attempts to demonstrate, the history of PID is intertwined with the development of modern medicine and is the direct result of the innovative thinking of physician scientists who introduced new concepts in pathology, microbiology, biochemistry, and immunology, based on carefully designed experiments. As a consequence of the novel ideas put forth in the late 19th century, progress in public health, the discovery of antimicrobials, and the utilization of biologic products led to the recognition of genetically determined defects of Immunity and the design of effective treatment strategies. RECENT
FINDINGS: The discovery of the structure of DNA, its replication, and the mapping of the human genome has transformed the field of PID into a predictable science of cutting edge therapies and diagnostic concepts.
SUMMARY: This review illustrates the historic events that led to the discovery, classification, and molecular definition of PID.

Entities:  

Mesh:

Year:  2012        PMID: 23095909     DOI: 10.1097/ACI.0b013e32835923a6

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  12 in total

Review 1.  The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases.

Authors:  Joshua D Milner; Steven M Holland
Journal:  Nat Rev Immunol       Date:  2013-07-26       Impact factor: 53.106

Review 2.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

3.  Primary immunodeficiencies in Central and Eastern Europe-the power of networking Report on the activity of the Jeffrey Modell Foundation Centers Network in Central and Eastern Europe.

Authors:  A Sediva; M Bataneant; M Belevtsev; A Blaziene; P Ciznar; E Förster-Waldl; J Kelecic; J Marodi; E Naumova; G Nasrullayeva; K Ress; M Serban; B Sitkauskiene; B Toth; V Modell; F Modell; V Tenembaum; M Marković; T Avcin
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

Review 4.  Overview of Immunodeficiency Disorders.

Authors:  Nikita Raje; Chitra Dinakar
Journal:  Immunol Allergy Clin North Am       Date:  2015-08-25       Impact factor: 3.479

5.  Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery.

Authors:  Vicki Modell; Megan Knaus; Fred Modell; Chaim Roifman; Jordan Orange; Luigi D Notarangelo
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

Review 6.  Intravenous immunoglobulin therapy: a snapshot for the internist.

Authors:  Gianfranco Vitiello; Giacomo Emmi; Elena Silvestri; Gerardo Di Scala; Boaz Palterer; Paola Parronchi
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 5.472

7.  Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.

Authors:  Hirokazu Kanegane; Kohsuke Imai; Masafumi Yamada; Hidetoshi Takada; Tadashi Ariga; Martin Bexon; Mikhail Rojavin; Wilson Hu; Midori Kobayashi; John-Philip Lawo; Shigeaki Nonoyama; Toshiro Hara; Toshio Miyawaki
Journal:  J Clin Immunol       Date:  2014-02-07       Impact factor: 8.317

Review 8.  A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis.

Authors:  Kyung-Yil Lee
Journal:  Infect Chemother       Date:  2015-03-30

9.  Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.

Authors:  Morna J Dorsey; Viet Ho; Mohsen Mabudian; Pere Soler-Palacín; Nerea Domínguez-Pinilla; Radha Rishi; Rahul Rishi; Duane Wong; Mikhail Rojavin; Alphonse Hubsch; Melvin Berger
Journal:  J Clin Immunol       Date:  2014-07-01       Impact factor: 8.317

10.  Immunocompromised patients: Review of the most common infections happened in 446 hospitalized patients.

Authors:  Mohsen Meidani; Alireza Emami Naeini; Mojtaba Rostami; Roya Sherkat; Katayoun Tayeri
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.